Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Dupilumab treatment improves signs, symptoms, and quality of life in children aged 6 months to 11 years with moderate-to-severe atopic dermatitis: a plain language summary.
Journal: The Journal of dermatological treatment
Published: August 24, 2026
Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: August 04, 2025
Dupilumab treatment reduces caregiver-reported skin pain in patients with moderate-to-severe atopic dermatitis aged 6 months to 5 years.
Journal: Frontiers in pediatrics
Published: June 10, 2024
Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Journal: Advances in therapy
Published: May 02, 2024
The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 study.
Journal: Journal of the American Academy of Dermatology
Published: March 05, 2024
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Journal: Advances in therapy
Published: September 15, 2023
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis.
Journal: Pediatric dermatology
Published: September 07, 2023
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.
Journal: Acta dermato-venereologica
Published: June 08, 2023
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.
Journal: Dermatology and therapy
Published: June 02, 2023
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years.
Journal: Dermatology and therapy
Published: March 02, 2023
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Journal: Paediatric drugs
Published: December 06, 2022
Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey).
Journal: Dermatology and therapy
Published: September 28, 2022
Last Updated: 09/26/2026